

Lisa Vandermeer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/440835/publications.pdf>

Version: 2024-02-01

60
papers

509
citations

686830

13
h-index

794141

19
g-index

61
all docs

61
docs citations

61
times ranked

478
citing authors

#	ARTICLE	IF	CITATIONS
1	A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2021, 142, 132-140.	1.3	42
2	Risk Modelâ€“Guided Antiemetic Prophylaxis vs Physicianâ€™s Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 225.	3.4	37
3	Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review. <i>Supportive Care in Cancer</i> , 2021, 29, 925-943.	1.0	28
4	Novel Methodology for Comparing Standard-of-Care Interventions in Patients With Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, e1016-e1024.	2.5	26
5	Optimal Management of Leptomeningeal Carcinomatosis in Breast Cancer Patientsâ€“A Systematic Review. <i>Clinical Breast Cancer</i> , 2016, 16, 456-470.	1.1	26
6	A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 615-624.	1.1	25
7	De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 507-517.	1.1	23
8	Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxelâ€“cyclophosphamide chemotherapy for breast cancer: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 1-10.	1.1	22
9	Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors. <i>Supportive Care in Cancer</i> , 2016, 24, 1563-1569.	1.0	19
10	Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases. <i>SpringerPlus</i> , 2014, 3, 577.	1.2	18
11	A randomized trial comparing vascular access strategies for patients receiving chemotherapy with trastuzumab for early-stage breast cancer. <i>Supportive Care in Cancer</i> , 2020, 28, 4891-4899.	1.0	17
12	Choice of study endpoint significantly impacts the results of breast cancer trials evaluating chemotherapy-induced nausea and vomiting. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 337-344.	1.1	15
13	Creating a pragmatic trials program for breast cancer patients: Rethinking Clinical Trials (REaCT). <i>Breast Cancer Research and Treatment</i> , 2019, 177, 93-101.	1.1	15
14	Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey. <i>Journal of Bone Oncology</i> , 2021, 26, 100339.	1.0	10
15	De-escalating adjuvant therapies in older patients with lower risk estrogen receptor-positive breast cancer treated with breast-conserving surgery: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 99, 102254.	3.4	10
16	Cost analysis of using Magee scores as a surrogate of Oncotype DX for adjuvant treatment decisions in women with early breast cancer. <i>Journal of Evaluation in Clinical Practice</i> , 2020, 26, 889-892.	0.9	9
17	The COVID-19 pandemic: An opportunity to rethink and harmonise the frequency of follow-up visits for patients with early stage breast cancer. <i>Cancer Treatment Reviews</i> , 2021, 97, 102188.	3.4	9
18	Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression. <i>Oncology Letters</i> , 2014, 7, 866-870.	0.8	8

#	ARTICLE	IF	CITATIONS
19	Enhancing accrual to chemotherapy trials for patients with early stage triple-negative breast cancer: a survey of physicians and patients. <i>Supportive Care in Cancer</i> , 2017, 25, 1881-1886.	1.0	8
20	Does integration of Magee equations into routine clinical practice affect whether oncologists order the Oncotype DX test? A prospective randomized trial. <i>Journal of Evaluation in Clinical Practice</i> , 2019, 25, 196-204.	0.9	8
21	Time to Update Evidence-Based Guideline Recommendations About Concurrent Tamoxifen and Antidepressant Use? A Systematic Review. <i>Clinical Breast Cancer</i> , 2022, 22, e362-e373.	1.1	8
22	Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review. <i>Journal of Global Oncology</i> , 2018, 4, 1-8.	0.5	7
23	A multicentre, randomized pilot trial comparing vascular access strategies for early stage breast cancer patients receiving non-trastuzumab containing chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 337-345.	1.1	7
24	Physician Survey of Timing of Adjuvant Endocrine Therapy Relative to Radiotherapy in Early Stage Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2019, 19, e40-e47.	1.1	7
25	Selecting Patients for Oncotype DX Testing Using Standard Clinicopathologic Information. <i>Clinical Breast Cancer</i> , 2020, 20, 61-67.	1.1	7
26	Feasibility outcomes of a randomised, multicentre, pilot trial comparing standard 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early stage breast cancer. <i>Journal of Bone Oncology</i> , 2021, 26, 100343.	1.0	6
27	A prospective multi-centre, randomized study comparing the addition of tapering dexamethasone to other standard of care therapies for taxane-associated pain syndrome (TAPS) in breast cancer patients. <i>Supportive Care in Cancer</i> , 2021, 29, 5787-5795.	1.0	6
28	Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 477-486.	1.1	6
29	Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey. <i>Supportive Care in Cancer</i> , 2021, 29, 6903-6912.	1.0	6
30	Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer. <i>Journal of Bone Oncology</i> , 2021, 30, 100388.	1.0	6
31	Experiences and Perceptions of Older Adults with Lower-Risk Hormone Receptor-Positive Breast Cancer about Adjuvant Radiotherapy and Endocrine Therapy: A Patient Survey. <i>Current Oncology</i> , 2021, 28, 5215-5226.	0.9	6
32	Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC). <i>Supportive Care in Cancer</i> , 2019, 27, 1345-1354.	1.0	5
33	The Rethinking Clinical Trials (REaCT) Program. A Canadian-Led Pragmatic Trials Program: Strategies for Integrating Knowledge Users into Trial Design. <i>Current Oncology</i> , 2021, 28, 3959-3977.	0.9	5
34	Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers. <i>Supportive Care in Cancer</i> , 2022, 30, 3977-3984.	1.0	5
35	Vasomotor symptoms in early breast cancer: a "real world" exploration of the patient experience. <i>Supportive Care in Cancer</i> , 2022, 30, 4437-4446.	1.0	5
36	A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer. <i>Current Oncology</i> , 2021, 28, 5073-5083.	0.9	5

#	ARTICLE	IF	CITATIONS
37	A scoping review characterizing "Choosing Wisely®" recommendations for breast cancer management. Breast Cancer Research and Treatment, 2021, 185, 533-547.	1.1	4
38	Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalation. Journal of Bone Oncology, 2021, 27, 100351.	1.0	4
39	A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia. Breast, 2021, 58, 42-49.	0.9	4
40	Patient perceptions about potential side effects and benefits from chemotherapy agents.. Journal of Clinical Oncology, 2013, 31, 6595-6595.	0.8	4
41	A randomized clinical trial comparing physician-directed or fixed-dose steroid replacement strategies for incomplete dexamethasone dosing prior to docetaxel chemotherapy. Supportive Care in Cancer, 2021, 29, 3113-3120.	1.0	3
42	Lost in Transition? Thoughts on Retirement, Part 2. "Should I Stay or Should I Go Now?" Oncologist, 2021, 26, e1290-e1295.	1.9	3
43	Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer. Current Oncology, 2021, 28, 1847-1856.	0.9	3
44	Developing patient-centred strategies to optimize the management of vasomotor symptoms in breast cancer patients: a survey of health care providers. Breast Cancer Research and Treatment, 2021, 188, 343-350.	1.1	3
45	Does the Time of Day at Which Endocrine Therapy Is Taken Affect Breast Cancer Patient Outcomes?. Current Oncology, 2021, 28, 2523-2528.	0.9	2
46	Using machine learning to predict individual patient toxicities from cancer treatments. Supportive Care in Cancer, 2022, 30, 7397-7406.	1.0	2
47	Clinical utility of a prediction tool to differentiate between breast cancer patients at high or low risk of chemotherapy-induced nausea and vomiting. Supportive Care in Cancer, 2021, 29, 7837-7843.	1.0	1
48	A randomized, double-blind trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronate in patients with high-risk bone metastases from breast cancer (The Odyssey) Tj ETQq0 0 OrgBT /Overlock 10 T		
49	A multicenter study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of taxotere/cyclophosphamide-induced febrile neutropenia in patients with early-stage breast cancer.. Journal of Clinical Oncology, 2020, 38, 7001-7001.	0.8	1
50	Efficacy and toxicity of extending bone modifying agents beyond two years for bone metastases in breast or castrate-resistant prostate cancer patients: A systematic review.. Journal of Clinical Oncology, 2020, 38, e24083-e24083.	0.8	1
51	Oral magnesium supplements for cancer treatment-induced hypomagnesemia: Results from a pilot randomized trial. Health Science Reports, 2021, 4, e443.	0.6	1
52	Abstract PS9-47: A scoping review characterizing "choosing wisely" recommendations for breast cancer management. , 2021, , .		0
53	Serum activinA and TGF- β 2 as biomarkers of breast cancer bone metastasis behavior.. Journal of Clinical Oncology, 2012, 30, 10620-10620.	0.8	0
54	Should de-escalation of bone-targeted agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis.. Journal of Clinical Oncology, 2015, 33, e17711-e17711.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Weight control strategies in breast cancer patients: A systematic review.. Journal of Clinical Oncology, 2016, 34, 179-179.	0.8	0
56	Optimal weight control strategies in cancer patients: A systematic review.. Journal of Clinical Oncology, 2016, 34, 10109-10109.	0.8	0
57	A multi-centre study to investigate the natural history of taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast or prostate cancer.. Journal of Clinical Oncology, 2016, 34, e21594-e21594.	0.8	0
58	Abstract OT2-21-01: A randomized, multicenter pragmatic trial comparing bone pain from a single dose of pegfilgrastim to 5 doses of daily filgrastim in breast cancer patients receiving neoadjuvant/adjuvant chemotherapy (REaCT-5G). Cancer Research, 2022, 82, OT2-21-01-OT2-21-01.	0.4	0
59	Abstract OT1-11-02: A pragmatic, randomised, multicentre trial evaluating the dose timing (morning vs Tj ETQq1 1 0.784314 rgBT /Ove Cancer Research, 2022, 82, OT1-11-02-OT1-11-02.	0.4	0
60	Will COVID-19 directives to reduce regularly scheduled physical examinations affect recurrence detection in patients with early breast cancer?. Journal of Clinical Oncology, 2022, 40, 1532-1532.	0.8	0